NCT05735717RecruitingPhase 2
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies
Source: ClinicalTrials.gov · Last updated 6 Apr 2026
Brief summary (registry, in English)
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety/feasibility study of the investigational procedure/product.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 10 Jan 2023
- Start date
- 11 May 2023
- Primary completion date
- 30 Nov 2027
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Diseases
- Acute lymphoblastic leukaemia, Myelodysplastic syndromes, Acute myeloid leukemia, Childhood cancers
- NCT number
- NCT05735717
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 70
- From 11 May 2023 to the primary completion date, 30 Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any prior autologous or allogeneic transplant
Other illness
- Active uncontrolled infection within 1 week of starting preparative therapy
- Known seropositive for HIV or known active Hepatitis B or C infection with detectable viral load by PCR.
- Active central nervous system malignancy
Other
- Pregnant or breastfeeding.
- CML blast crisis
Who the study is looking for
- Histological confirmation of hematological malignancies
- Acute leukemias
- Acute Myeloid Leukemia (AML) and related precursor neoplasms
- Favorable risk AML is defined as having one of the following:
- Acute lymphoblastic leukemia (ALL)/lymphoma
- Myelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia with severe pancytopenia, transfusion dependence, or high risk cytogenetics or molecular features.
- Age 60 years of age or younger at the time of consent
- Karnofsky performance status ≥ 70% or Lansky play score 50% for ≤16 years of age.
- Adequate organ function
Age in the registry: - to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Minnesota/Masonic Cancer Center Coordinator of this site? Confirm its status | Minneapolis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.